FDA Authorizes Updated Novavax COVID Vaccine

The U.S. FDA granted emergency use authorization for Novavax's updated COVID-19 shot. Suitable for individuals 12 and older, it targets the JN.1 strain. This authorization offers an additional vaccine option, complementing the updated Pfizer and Moderna vaccines approved earlier this month for the KP.2 variant.

The U.S. Food and Drug Administration has granted emergency use authorization for an updated version of Novavax's COVID-19 vaccine, targeting the JN.1 strain of the virus.

The updated vaccine has been authorized for use in individuals 12 years and older, adding another option for COVID-19 immunization. "Today’s authorization provides an additional COVID-19 vaccine option," said Peter Marks, director of the FDA's Center for Biologics Evaluation and Research.

Earlier this month, the FDA approved updated COVID-19 vaccines from Pfizer and Moderna, designed to target the KP.2 variant that was prevalent earlier this year.